PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28279662-11 2017 We also studied PPARalpha in nicotine dependence by evaluating its activation in nicotine withdrawal. Nicotine 29-37 peroxisome proliferator activated receptor alpha Mus musculus 16-25 29567093-7 2019 Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward. Nicotine 210-218 peroxisome proliferator activated receptor alpha Mus musculus 120-130 29567093-7 2019 Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward. Nicotine 210-218 peroxisome proliferator activated receptor alpha Mus musculus 140-150 29567093-7 2019 Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward. Nicotine 210-218 peroxisome proliferator activated receptor alpha Mus musculus 140-150 29567093-7 2019 Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward. Nicotine 309-317 peroxisome proliferator activated receptor alpha Mus musculus 140-150 29567093-7 2019 Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward. Nicotine 309-317 peroxisome proliferator activated receptor alpha Mus musculus 140-150 28279662-7 2017 The present study investigated PPARalpha as a possible mediator of the effect of alpha7 nAChR activation in nicotine dependence. Nicotine 108-116 peroxisome proliferator activated receptor alpha Mus musculus 31-40 28279662-8 2017 Our results demonstrate the PPARalpha antagonist GW6471 blocks actions of the alpha7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice. Nicotine 112-120 peroxisome proliferator activated receptor alpha Mus musculus 28-37 28279662-9 2017 These findings suggests that alpha7 nAChR activation attenuates nicotine CPP in a PPARalpha-dependent manner. Nicotine 64-72 peroxisome proliferator activated receptor alpha Mus musculus 82-91 28279662-10 2017 To evaluate PPARalpha activation in nicotine dependence we used the selective and potent PPARalpha agonist, WY-14643 and the clinically used PPARalpha activator, fenofibrate, in nicotine CPP and we observed attenuation of nicotine preference, but fenofibrate was less potent. Nicotine 36-44 peroxisome proliferator activated receptor alpha Mus musculus 12-21 28279662-11 2017 We also studied PPARalpha in nicotine dependence by evaluating its activation in nicotine withdrawal. Nicotine 81-89 peroxisome proliferator activated receptor alpha Mus musculus 16-25 28279662-13 2017 This suggests that PPARalpha plays a role in nicotine reward and withdrawal and that further studies are warranted to elucidate its function in mediating the effects of alpha7 nAChRs in nicotine dependence. Nicotine 45-53 peroxisome proliferator activated receptor alpha Mus musculus 19-28 28279662-13 2017 This suggests that PPARalpha plays a role in nicotine reward and withdrawal and that further studies are warranted to elucidate its function in mediating the effects of alpha7 nAChRs in nicotine dependence. Nicotine 186-194 peroxisome proliferator activated receptor alpha Mus musculus 19-28 20570248-5 2010 Among these, endogenous ligands to the nuclear receptor-transcription factor peroxisome proliferator-activated receptors type-alpha (PPARalpha) have been recently found to suppress nicotine-induced responses of dopamine neurons. Nicotine 181-189 peroxisome proliferator activated receptor alpha Mus musculus 133-142 23724059-6 2013 Previous studies demonstrated that peroxisome proliferator-activated receptors-alpha (PPARalpha), nuclear receptor transcription factors, suppress nicotine-induced behavioral and electrophysiological effects by modulating nAChRs containing beta2 subunits. Nicotine 147-155 peroxisome proliferator activated receptor alpha Mus musculus 86-95 23724059-7 2013 On these bases, we tested whether PPARalpha agonists were protective against nicotine-induced seizures. Nicotine 77-85 peroxisome proliferator activated receptor alpha Mus musculus 34-43 23724059-14 2013 We found that both acute and chronic treatment with PPARalpha agonists abolished nicotine-induced sIPSC increases. Nicotine 81-89 peroxisome proliferator activated receptor alpha Mus musculus 52-61 20570248-9 2010 Additionally, PPARalpha activation in vivo reduces both the number of spontaneously active dopamine neurons and nicotine-induced increased locomotion. Nicotine 112-120 peroxisome proliferator activated receptor alpha Mus musculus 14-23 20570248-11 2010 Thus, PPARalpha ligands might prove beneficial in treating disorders in which dopamine dysfunction plays a prominent role, such as schizophrenia and nicotine addiction. Nicotine 149-157 peroxisome proliferator activated receptor alpha Mus musculus 6-15 33892114-4 2021 In this study, we investigated whether PPARalpha activation also blocks nicotine-enhanced AFL. Nicotine 72-80 peroxisome proliferator activated receptor alpha Mus musculus 39-48 33892114-13 2021 In conclusion, PPARalpha activation by WY-14,643 attenuates alcohol/nicotine-induced fatty liver but deteriorates ethanol/nicotine-induced liver injury; WY-14,643 enhances ethanol metabolism via induction of catalase. Nicotine 68-76 peroxisome proliferator activated receptor alpha Mus musculus 15-24 33892114-13 2021 In conclusion, PPARalpha activation by WY-14,643 attenuates alcohol/nicotine-induced fatty liver but deteriorates ethanol/nicotine-induced liver injury; WY-14,643 enhances ethanol metabolism via induction of catalase. Nicotine 122-130 peroxisome proliferator activated receptor alpha Mus musculus 15-24